Drugs targeting the sarcomere in heart failure and hypertrophic cardiomyopathy

Nature Reviews Cardiology, Published online: 01 December 2020; doi:10.1038/s41569-020-00488-yOmecamtiv mecarbil (a myosin activator) and mavacamten (a myosin inhibitor) have beneficial effects in patients with heart failure with reduced ejection fraction or obstructive hypertrophic cardiomyopathy, respectively.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research